Moleculin Biotech’s Abstract Gains Acceptance for Presentation at International Leukemia Symposium

Moleculin Biotech's Significant Achievement in Cancer Treatment

Moleculin Biotech, Inc., a prominent player in the pharmaceutical industry, has recently made a notable announcement regarding its research into treatments for aggressive forms of cancer. The company reported that its abstract has been accepted for a poster presentation at the upcoming Acute Leukemias XIX (ISALXIX) International Symposium, scheduled for March 16-19, 2025, in Munich, Germany. This acceptance marks an important milestone for the company and highlights its commitment to fighting hard-to-treat tumors and viral infections.

The abstract, denoted as P002, falls under the session focused on clinical studies relating to Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL). The presentation will center on the use of Liposomal Annamycin in conjunction with Cytarabine for the treatment of AML. Dr. Cristina Papayannidis, an esteemed Adjunct Professor in the Department of Medical and Surgical Sciences at the University of Bologna, Italy, will be the presenting author. Dr. Papayannidis' expertise is anticipated to provide invaluable insights into the potential breakthroughs in treating this challenging disease.

Moleculin Biotech has established itself as a late-stage pharmaceutical company that is paving the way in the field of oncology with a diverse portfolio of drug candidates. Its lead program, Annamycin, is a next-generation anthracycline designed to circumvent the common multidrug resistance encountered in cancer treatment. Furthermore, Annamycin aims to eliminate the cardiotoxic side effects commonly associated with traditional anthracyclines, making it a promising option for patients undergoing treatment for relapsed or refractory AML as well as soft tissue sarcoma with lung metastases.

In addition to Annamycin, the company is preparing to initiate a pivotal Phase 3 clinical trial known as the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial. This adaptive design study, dubbed MB-108, will evaluate the efficaciousness of Annamycin in combination with cytarabine—together referred to as AnnAraC—targeting patients suffering from relapsed or refractory AML. Following the success of an earlier Phase 1B/2 trial with positive feedback from the FDA, Moleculin believes it has effectively mitigated risks associated with this next phase, paving the way for a potential approval of Annamycin in treating AML.

Moreover, the innovative company is also advancing its development of WP1066, an immune/transcription modulator. This compound has been shown to inhibit the oncogenic transcription factor p-STAT3 while stimulating a natural immune response, showing promise in treating brain tumors, pancreatic cancers, and more. Additionally, Moleculin is progressing a range of antimetabolites, such as WP1122, which holds potential for treating viral pathogens alongside certain cancer types.

To stay updated on Moleculin Biotech and its cutting-edge research, visit their official website at www.moleculin.com. Investors and stakeholders can also connect with the company through social media platforms including X, LinkedIn, and Facebook. This presentation at the ISALXIX symposium underscores Moleculin's ongoing commitment to finding innovative solutions to complex medical challenges, emphasizing its role as a leader in the pharmaceutical industry dedicated to making strides in cancer treatment.